hotspot -WSS

hotspot

author：entertainment 2025-10-01 17:20:14 - browse：68

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a new approach to treating ulcerative colitis, a chronic inflammatory disease that can cause intense gastrointestinal pain and distress.

The therapy, dubbed Omvoh, is an antibody that blocks IL-23p19, an immune signaling molecule that plays a key role in sustaining the disease. It’s the first treatment to target this particular pathway in ulcerative colitis. The drug’s approval comes after two late-stage trials found that patients taking Omvoh showed a significant improvement in symptoms after both three months and a year compared with those given a placebo, and that the therapy had minimal side effects.

Omvoh’s list price will be $9,593 per month for intravenous delivery and $10,360 per dose injected beneath the skin. A company spokesperson told STAT that patients who have the drug covered by commercial insurance may pay as little as $5 per month for up to 30 months.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Former reverend arrested for allegedly killing 8

WSS

New Alzheimer's drugs heat up race for early detection blood tests

Statins may not be needed by millions of people, study suggests

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Roche’s Alnylam deal shows drug firms interested in heart drugs

Statins may not be needed by millions of people, study suggests

UHS says company favors patients whose insurance pays more

leisure time

hotspot

Wikipedia

Apple is now the first public company to be valued at $3 trillion

STAT Virtual Event: ASCO Recap, Live!

Dobbs anniversary: the lost opportunity of abortion as health care

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Trump demands the U.S. pay no more for drugs than other countries … again

Cigna wins case to block Amy Bricker's move to CVS

FDA approval of Sarepta Duchenne genetic therapy gives me hope

CDC Director Mandy Cohen on transparency, trust, and health

Affirmative action in medical school literally saved lives

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Wikipedia

5 takeaways from STAT's examination of Zynex Medical

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Democrats decry new health bill for going easy on private equity

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Teladoc has a new CEO, but challenges remain the same

Deposition: Sackler embraced plan to conceal OxyContin’s strength

hotspot

focus

hotspot

entertainment